

Special Issue

Gene Delivery Vectors and Physical Methods: Present and Future Trends

Message from the Guest Editor

The past few decades have witnessed the evolution of gene medicine from an experimental technology into a viable strategy for developing therapeutics for a wide range of disorders. One of the significant advantages of nucleic acid drugs over currently available low-molecular-weight pharmaceuticals is their selective recognition of molecular targets and pathways, which imparts tremendous specificity of action. Despite such potential, therapeutic success still largely depends on the development of safe and effective ways to deliver nucleic acids within targeted cells. Gene delivery technologies are therefore in the limelight. Moreover, high-throughput technologies—that is, a reliable tool for pre-clinical testing and further improvement of gene delivery vectors and/or nucleic acid drugs—continue to be developed.

The possible topics include, but are not limited to the following:

Non-viral gene delivery vectors
Viral gene delivery vectors
Electroporation technology
Sonoporation technology
Photoporation technology
Magnetofection technology
Hydroporation technology
Biolistic or gene gun technology
High-throughput gene delivery technologies

Guest Editor

Prof. Dr. Gabriele Candiani

Department of Chemistry, Materials and Chemical Engineering "Giulio Natta", Politecnico di Milano, 20131 Milan, Italy

Deadline for manuscript submissions

closed (31 October 2020)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/31282

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).